CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 430 enrolled
Drug / intervention
Fluticasone Furoate/Vilanterol +5 moredrug
Likely dose
Fluticasone Furoate 100 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02094937
NCT02094937Phase 3Completed

201135 : A Randomised, Double-blind, Multicenter, Parallel-group Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Subjects Stepped Down From a Maintenance Therapy With RELVAR® Inhaler (FF/VI) 100/25 mcg Once-daily in Japanese Subjects

GlaxoSmithKline·interventional·Posted Mar 24, 2014·Updated May 25, 2017

In Brief

A Phase 3 clinical trial evaluating Fluticasone Furoate/Vilanterol, Fluticasone Furoate 100 mcg, and 4 other interventions for Asthma. Completed, enrolled 430 participants across 33 sites.

Detailed Summary

The primary aim of this study is to clarify the position of FF and FF/Vilanterol (VI) 100/25 micrograms (mcg) compared with existing therapies by assessing FF dosage equivalent to low to middle-dose inhaled corticosteroids (ICS). The study is divided into Run-in period, Period 1 (open-label treatment), Period 2 (double blind treatment) and Follow-up. Subjects with well controlled asthma after completing a run-in period of 4 weeks will be switched from middle-dose ICS/long acting beta 2 agonist (LABA) equivalent dose to once-daily FF/VI 100/25 mcg for an 8 weeks treatment period (Period 1). After this, subjects will be randomized in a 1:1:1 ratio to receive either FP 250 mcg twice daily, FP 100 mcg twice daily or FF 100 mcg once daily in a 12 week double blind treatment period (Period 2). There will be a 1 week Follow-up Period following completion of the double-blind treatment period, or early withdrawal from the study. Overall , the total duration of subject's participation in the study will be for 25 weeks. RELVAR is a registered trademark of the GSK group of companies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 24, 2014
Enrollment StartMar 27, 2014
Primary CompletionAug 28, 2015
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.3 years ago

Interventions

Fluticasone Furoate/Vilanteroldrug

FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler

Fluticasone Furoate 100 mcgdrug

FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler

Fluticasone Propionate 250 mcgdrug

FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler

Fluticasone Propionate 100 mcgdrug

FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler

Fluticasone Furoate Placebodrug

Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler

Fluticasone Propionate Placebodrug

Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler